Earnings Growth & Price Strength Make HCA Healthcare (HCA) a Stock to Watch

Zacks is promoting its 'Focus List,' a 50-stock portfolio designed for long-term investors, highlighting its significant historical outperformance against the S&P 500, including a 13.85% gain in 2020 versus the S&P's 9.38%, and a cumulative 2,519.23% return since 1996 (February 1996 - March 2021). This strategy leverages earnings estimate revisions and the proprietary Zacks Rank (#1 or #2 rated companies) to identify stocks with strong buy ratings, exemplified by HCA Healthcare, which has seen a 163.5% increase since its 2019 inclusion and recent upward earnings estimate revisions for FY24.

Analysis

The provided text outlines the investment methodology and historical performance of the Zacks Focus List, a 50-stock portfolio built on the principle of upward earnings estimate revisions. The strategy's claimed efficacy is supported by significant historical outperformance, with the Focus List reportedly generating a 13.85% annualized gain in 2020 versus the S&P 500's 9.38%, and a cumulative return of 2,519.23% from February 1996 to March 2021, far exceeding the index's 854.95% return over the same period. HCA Healthcare (HCA) is presented as a prime example of the strategy's success, having appreciated 163.5% since its inclusion in January 2019. The fundamental case for HCA remains robust, with seven analysts revising their fiscal 2024 earnings estimates upward in the last 60 days, pushing the Zacks Consensus Estimate to $20.84. This is complemented by an expected earnings growth of 9.6% for the current fiscal year and a consistent history of positive earnings surprises averaging 5.6%. Notably, despite these positive indicators and its long-term success on the list, HCA currently holds a Zacks Rank of #3 (Hold), suggesting that the near-term catalysts for outperformance may be perceived as less potent than when it was originally selected.

Key Decisions for Investors

• Investors could consider incorporating a strategy that prioritizes companies with consistent upward earnings estimate revisions into their own stock selection framework, given the historical outperformance cited for the Zacks Focus List.
• For those evaluating HCA Healthcare, the recent upward revisions to its FY2024 earnings consensus and a projected 9.6% earnings growth signal continued fundamental strength and a positive outlook from analysts.
• Despite the strong fundamental narrative for HCA, its current Zacks Rank of #3 (Hold) suggests that investors should weigh the positive long-term outlook against potentially moderating short-term price momentum.